These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9773734)

  • 1. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis.
    Farup CE; Leidy NK; Murray M; Williams GR; Helbers L; Quigley EM
    Diabetes Care; 1998 Oct; 21(10):1699-706. PubMed ID: 9773734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group.
    Silvers D; Kipnes M; Broadstone V; Patterson D; Quigley EM; McCallum R; Leidy NK; Farup C; Liu Y; Joslyn A
    Clin Ther; 1998; 20(3):438-53. PubMed ID: 9663360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis.
    Patterson D; Abell T; Rothstein R; Koch K; Barnett J
    Am J Gastroenterol; 1999 May; 94(5):1230-4. PubMed ID: 10235199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis.
    Soykan I; Sarosiek I; McCallum RW
    Am J Gastroenterol; 1997 Jun; 92(6):976-80. PubMed ID: 9177513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary.
    Heckert J; Parkman HP
    Neurogastroenterol Motil; 2018 Jan; 30(1):. PubMed ID: 29110425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis.
    Dumitrascu DL; Weinbeck M
    Am J Gastroenterol; 2000 Jan; 95(1):316-7. PubMed ID: 10638616
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.
    Parkman HP; Jacobs MR; Mishra A; Hurdle JA; Sachdeva P; Gaughan JP; Krynetskiy E
    Dig Dis Sci; 2011 Jan; 56(1):115-24. PubMed ID: 21063774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domperidone is more effective than cisapride in children with diabetic gastroparesis.
    Franzese A; Borrelli O; Corrado G; Rea P; Di Nardo G; Grandinetti AL; Dito L; Cucchiara S
    Aliment Pharmacol Ther; 2002 May; 16(5):951-7. PubMed ID: 11966504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort.
    Schey R; Saadi M; Midani D; Roberts AC; Parupalli R; Parkman HP
    Dig Dis Sci; 2016 Dec; 61(12):3545-3551. PubMed ID: 27530760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of poor mental health in adult spinal deformity patients with poor physical function: a retrospective analysis with a 2-year follow-up.
    Bakhsheshian J; Scheer JK; Gum JL; Hostin R; Lafage V; Bess S; Protopsaltis TS; Burton DC; Keefe MK; Hart RA; Mundis GM; Shaffrey CI; Schwab F; Smith JS; Ames CP;
    J Neurosurg Spine; 2017 Jan; 26(1):116-124. PubMed ID: 27541847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee.
    Zhao SZ; Dedhiya SD; Bocanegra TS; Fort JG; Kuss ME; Rush SM
    Clin Ther; 1999 Jan; 21(1):205-17. PubMed ID: 10090436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study.
    Parkman HP; Carlson MR; Gonyer D
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1256-1263.e1. PubMed ID: 25576687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic gastroparesis: treatment with domperidone--a double-blind, placebo-controlled trial.
    Heer M; Müller-Duysing W; Benes I; Weitzel M; Pirovino M; Altorfer J; Schmid M
    Digestion; 1983; 27(4):214-7. PubMed ID: 6653921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Domperidone: a peripherally acting dopamine2-receptor antagonist.
    Barone JA
    Ann Pharmacother; 1999 Apr; 33(4):429-40. PubMed ID: 10332535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis.
    Sugumar A; Singh A; Pasricha PJ
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):726-33. PubMed ID: 18524689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study on Tangweikang in treating diabetic gastroparesis].
    Jiang RQ; Zhang DX; Bai CY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Feb; 27(2):114-6. PubMed ID: 17342995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis.
    McCallum RW; Lembo A; Esfandyari T; Bhandari BR; Ejskjaer N; Cosentino C; Helton N; Mondou E; Quinn J; Rousseau F;
    Neurogastroenterol Motil; 2013 Nov; 25(11):e705-17. PubMed ID: 23848826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials.
    Asha MZ; Khalil SFH
    Sultan Qaboos Univ Med J; 2019 Nov; 19(4):e291-e304. PubMed ID: 31897312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.
    Ejskjaer N; Wo JM; Esfandyari T; Mazen Jamal M; Dimcevski G; Tarnow L; Malik RA; Hellström PM; Mondou E; Quinn J; Rousseau F; McCallum RW
    Neurogastroenterol Motil; 2013 Feb; 25(2):e140-50. PubMed ID: 23279217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.